News Sanofi swoops on Dynavax with $2.5bn takeover deal Sanofi's last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5bn agreement to buy vaccine firm Dynavax.
News Dynavax has GSK's shingles vaccine in its sights Big pharma group GSK has been ruling the market for shingles vaccines for many years, but little Dynavax wants to knock off its crown.
R&D JP Morgan Week 2025 – Ryan Spencer Join CEO Ryan Spencer of Dynavax Technologies in a video interview discussing JP Morgan Week 2025
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.